Capital International Investors Trims Position in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Capital International Investors decreased its position in Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 16.2% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 2,664,793 shares of the company's stock after selling 515,348 shares during the quarter. Capital International Investors owned approximately 0.24% of Teva Pharmaceutical Industries worth $58,732,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. FMR LLC lifted its stake in shares of Teva Pharmaceutical Industries by 30.7% in the 4th quarter. FMR LLC now owns 81,983,231 shares of the company's stock worth $1,806,910,000 after purchasing an additional 19,242,468 shares during the period. Clal Insurance Enterprises Holdings Ltd increased its holdings in Teva Pharmaceutical Industries by 12.8% during the fourth quarter. Clal Insurance Enterprises Holdings Ltd now owns 38,962,773 shares of the company's stock valued at $859,935,000 after buying an additional 4,418,961 shares during the last quarter. Todd Asset Management LLC bought a new position in Teva Pharmaceutical Industries in the fourth quarter worth approximately $58,243,000. Marshall Wace LLP boosted its stake in shares of Teva Pharmaceutical Industries by 87.8% during the 4th quarter. Marshall Wace LLP now owns 5,155,402 shares of the company's stock worth $113,625,000 after acquiring an additional 2,410,420 shares during the last quarter. Finally, Raymond James Financial Inc. bought a new position in shares of Teva Pharmaceutical Industries in the fourth quarter worth about $38,914,000. 54.05% of the stock is owned by hedge funds and other institutional investors.

Teva Pharmaceutical Industries Stock Performance

Shares of Teva Pharmaceutical Industries stock traded up $0.16 during midday trading on Friday, hitting $14.88. The company had a trading volume of 2,756,419 shares, compared to its average volume of 12,277,618. The stock has a market cap of $16.87 billion, a price-to-earnings ratio of -10.26, a PEG ratio of 1.44 and a beta of 0.72. Teva Pharmaceutical Industries Limited has a 12-month low of $12.47 and a 12-month high of $22.80. The company has a quick ratio of 0.75, a current ratio of 0.98 and a debt-to-equity ratio of 2.97. The company has a fifty day simple moving average of $15.26 and a 200 day simple moving average of $17.58.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last posted its quarterly earnings data on Wednesday, January 29th. The company reported $0.70 EPS for the quarter, topping the consensus estimate of $0.69 by $0.01. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. As a group, analysts predict that Teva Pharmaceutical Industries Limited will post 2.5 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several analysts have recently commented on the stock. Barclays decreased their price objective on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating on the stock in a research report on Thursday, January 30th. Bank of America lowered their price objective on Teva Pharmaceutical Industries from $23.00 to $20.00 and set a "buy" rating for the company in a research note on Thursday, March 6th. UBS Group lowered their target price on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating for the company in a report on Thursday, January 30th. StockNews.com upgraded Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a research report on Wednesday. Finally, Piper Sandler increased their price target on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an "overweight" rating in a research report on Friday, January 17th. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $23.43.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.